The @ElrondNetwork ecosystem and dev community is really growing! Just last week Epunks | JewelSwap💎AMM/Loans @ App.Jewelswap.io held the first on-chain NFT mint and @BeskarDAO put up a really beautiful third-party marketplace I missed the ePunk mint, but bought a rare one on eMoon to support both projects

Interest rates across Europe are at record lows, making it harder for regular people to save money. Check out our deep dive to learn how we got here – and why crypto-powered earnings solutions like Nash’s can help! blog.nash.io/want-to-earn-h… #interestrates #DeFi $NEX

1/ Today is a grand day for Elrond, and the Maiar DEX. 🌕 Last days have been insane, hyper focused on putting all the pieces together for the launch. We are now almost ready. Here's the plan.

Our work on securing DEXs with MPC will be published in the IEEE Blockchain proceedings! You can check out Robert's talk on December 6th nsclab.org/blockchain2021…

Very cool! Just picked up mint #27

The ML models we're building at Vcreate would allow you to take a variant like Omicron and predict how well an existing population of T-cells (e.g., from prior illness or vaccine) might handle it Not quite there yet, but it's an interesting use case beyond T-cell discovery

Weatherwax Biotechnologies and Vcreate win our two Astellas Future Innovator Prizes, granting a year’s access to Molecules Biolabs incubator and our R&D mentors! We are proud to support these #entrepreneurs to advance their #innovations. #ScienceFirstForPatients

Thanks BIO Convention for giving us the opportunity to present Vcreate's work on cancer therapies and machine learning. #BIO2022

"TAPIR: a T-cell receptor language model for predicting rare and novel targets" A CNN trained on ~50,000 TCR sequences that learns to generate TCR representations with a number of downstream uses biorxiv.org/content/10.110…

Excited to share our work on TAPIR, a generalizable ML model that can predict TCR-target interaction! T-cell receptors (TCRs) are involved in most diseases, but linking their sequences with targets is an unsolved grand challenge in the field. biorxiv.org/content/10.110…

Excited to announce that Vcreate is joining the latest cohort of the Merck Digital Sciences Studio (MDS Studio), an accelerator for the next generation of technologies for drug discovery and development. Thanks for your support Merck Northpond Ventures NJIT @MerckDSS Microsoft

Another Preprint Club - Immunology Journal Club from Malcolm Sim describes a bioRxiv from Binbin Chen presenting TAPIR - a computational tool for predicting TCR-pMHC interactions rdcu.be/ds0oq

Section 174 aims to kill startups — we must take action Hi everyone 👋 David here, former accountant & CEO/Founder Fondo (taxes, tax credits, and bookkeeping on autopilot for 1,000+ busy tech founders). I have a small request for all founders today - it will only take 10